Published in Neth J Med on January 01, 1985
Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis (2002) 0.78
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med (2001) 4.39
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J (1977) 4.20
Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J (Clin Res Ed) (1983) 2.90
Analgesic nephropathy: clinical syndrome and prognosis. Br Med J (1971) 2.77
Post marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol (1987) 2.56
Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. Br Med J (Clin Res Ed) (1982) 2.40
Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med (1985) 2.07
The yellow card: mark II. BMJ (1990) 2.00
Death from thyrotoxicosis. Lancet (1973) 1.93
Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up. Br Med J (Clin Res Ed) (1985) 1.78
Benzodiazepine drugs in general medical patients. Br Med J (1976) 1.74
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut (2000) 1.69
Renin and acute renal failure: studies in man. Br Med J (1970) 1.66
Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients. Lancet (1982) 1.64
Adverse reactions to potassium chloride. Q J Med (1974) 1.60
Detection of drug-induced disease. Br J Clin Pharmacol (1979) 1.56
Blood loss in the Kolff twin-coil artificial kidney. Nephron (1970) 1.50
Effect of furosemide on antibiotic-induced renal damage in rats. J Infect Dis (1972) 1.46
Intensive hospital monitoring study of intravenous cimetidine. Arch Intern Med (1986) 1.38
Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol (2001) 1.33
Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis (1981) 1.33
Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. Lancet (1969) 1.31
Potassium supplements in patients receiving long-term diuretics for oedema. Q J Med (1976) 1.31
Record linkage study of hypokalaemia in hospitalized patients. Postgrad Med J (1986) 1.25
Hyponatraemia during carbamazepine treatment. Br Med J (1977) 1.25
Severe hypokalemia in hospitalized patients. Arch Intern Med (1979) 1.24
Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis (1982) 1.23
Continuous infusion of frusemide in refractory oedema. Br Med J (1978) 1.20
Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics (2000) 1.20
Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. Gut (1992) 1.20
Atracurium--a post-marketing surveillance study: methods and U.S. experience. Br J Anaesth (1989) 1.17
Alzheimer's disease in antacid users. Lancet (1989) 1.17
Protein-calorie undernutrition in hospitalized cancer patients. Am J Med (1980) 1.16
The nephrotoxicity of cephaloridine. Postgrad Med J (1970) 1.16
Metabolic approaches to cancer cachexia. Annu Rev Nutr (1982) 1.15
Adverse reactions to co-trimoxazole in hospitalized medical patients. Am J Med Sci (1978) 1.15
Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed) (1983) 1.13
Risk factors for adverse drug reactions--epidemiological approaches. Eur J Clin Pharmacol (1990) 1.11
Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin. Clin Pharmacol Ther (1977) 1.08
Characterization of autostimulatory and transforming growth factors from human melanoma cells. Cancer Res (1985) 1.05
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol (2001) 1.04
Life threatening drug reactions amongst medical in-patients. Scott Med J (1979) 1.03
Drug prescribing in hospitals: an international comparison. Am J Public Health (1976) 1.03
Drug monitoring of surgical patients. JAMA (1982) 1.03
Early mortality in the megaloblastic anaemias. Q J Med (1972) 1.03
Hyperalimentation of the cancer patient with protein-calorie undernutrition. Cancer Res (1981) 1.02
Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus. Q J Med (1991) 1.01
Extraction of a melanoma growth-stimulatory activity from culture medium conditioned by the Hs0294 human melanoma cell line. Cancer Res (1983) 1.01
Acute respiratory failure and CNS-depressing drugs. Postgrad Med J (1981) 1.00
The occurrence and clinical features of analgesic abuse in Western Scotland. Scott Med J (1968) 1.00
Urinary tract symptomatology in general practice. J R Coll Gen Pract (1973) 1.00
Pharmacoepidemiology: a new discipline. Br Med J (Clin Res Ed) (1984) 0.99
Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev (1984) 0.98
Uptake and transport of Imposil by the glomerular mesangium in the mouse. Lab Invest (1977) 0.98
Review: post-marketing surveillance of the safety of cimetidine--the problems of data interpretation. Aliment Pharmacol Ther (1987) 0.97
Screening for bacteriuria in pregnancy. Lancet (1971) 0.96
Analgesic consumption and impaired renal function. J Chronic Dis (1973) 0.96
The impact of near-patient testing on the organisation and costs of an anticonvulsant clinic. Ther Drug Monit (1990) 0.95
Coffee and tea consumption and breast disease. Surgery (1981) 0.94
Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas. J Invest Dermatol (1986) 0.94
Iron metabolism in patients with chronic renal failure. Clin Sci (1970) 0.94
Deaths from severe megaloblastic anaemia in hospitalised patients. Scand J Haematol (1976) 0.93
Postmarketing surveillance of captopril for hypertension. Br J Clin Pharmacol (1992) 0.92
Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun (2003) 0.92
Total parenteral nutrition as an adjunct to chemotherapy of metastatic colorectal cancer. Cancer Treat Rep (1981) 0.90
Diabetes mellitus and primary hepatocellular carcinoma. Q J Med (1986) 0.90
Adverse reactions to frusemide in hospital inpatients. Br Med J (1979) 0.90
Muscle biopsy water and electrolyte contents in chronic renal failure. Clin Sci (1970) 0.89
Reduced steady-state plasma concentrations of chlorpromazine and indomethacin in patients receiving cimetidine. Eur J Clin Pharmacol (1983) 0.89
Targeting of alanine: glyoxylate aminotransferase in normal individuals and its mistargeting in patients with primary hyperoxaluria type 1. Ann N Y Acad Sci (1996) 0.89
Identification of microbial dimethylarginine dimethylaminohydrolase enzymes. Mol Microbiol (1999) 0.87
Clobazam--a new hypnotic? Br J Clin Pharmacol (1978) 0.87
Acetylator phenotype in spontaneous SLE and rheumatoid arthritis. Ann Rheum Dis (1979) 0.87
Amoxycillin: pharmacokinetic studies in normal subjects, patients with pernicious anaemia and those with renal failure. Postgrad Med J (1974) 0.86
Antibacterial therapy in general medical wards. Postgrad Med J (1977) 0.86
Oral contraceptive use and venous thromboembolism: absence of an effect of smoking. Br Med J (1977) 0.86
Clinical studies on the effect of laevulose on the rate of metabolism of ethyl alcohol. Scott Med J (1969) 0.85
Intracellular localization of dimethylarginine dimethylaminohydrolase overexpressed in an endothelial cell line. Acta Physiol Scand (2000) 0.85
Drug attributed alterations in potassium handling in congestive cardiac failure. Eur J Clin Pharmacol (1982) 0.85
Preparation of a monoclonal antibody to a melanoma growth-stimulatory activity released into serum-free culture medium by Hs0294 malignant melanoma cells. J Cell Biochem (1987) 0.84
Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine. Clin Chem (1981) 0.84
Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol (2000) 0.84
Extended therapy with a trimethoprim-sulphonamide for the treatment of established urinary tract infection. Scott Med J (1971) 0.82
Renal papillary necrosis following phenacetin excess. Scott Med J (1967) 0.82
Interaction between warfarin and sulphamethoxazole. Postgrad Med J (1977) 0.82
Acrylamide poisoning. Postgrad Med J (1977) 0.82
In vitro growth promotion in human malignant melanoma cells by fibroblast growth factor. Cancer Res (1982) 0.81
Undesired effects of the sulphonylurea drugs. Adverse Drug React Acute Poisoning Rev (1985) 0.81
Effects of diabetic control and biosynthetic human insulin on blood rheology in established diabetics. Diabetes Res (1984) 0.81
Acute renal failure in the cold-agglutination syndrome. Lancet (1968) 0.80
The review of medicines in the United Kingdom. Br J Clin Pharmacol (1992) 0.80
Intravenous fluids in medical in-patients. Br J Clin Pharmacol (1977) 0.79
Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin. Cancer (1983) 0.79
Adverse drug reactions. Hum Toxicol (1985) 0.79
Adverse reactions to methyldopa with particular reference to hypotension. Am Heart J (1978) 0.79
Serum alpha-1 proteinase inhibitor in advanced cancer: mass variants and functionally inert forms. Cancer Res (1987) 0.78
Outcome of pregnancy in insulin-dependent (type 1) diabetic women between 1971 and 1984. Q J Med (1986) 0.78
Iron metabolism in patients with chronic renal failure on regular dialysis treatment. Clin Sci (1971) 0.78
Plasma inter-alpha-trypsin inhibitor-related urinary glycoprotein EDC1 inhibits the growth of a Burkitt's lymphoma cell line. J Cell Biochem (1990) 0.78